All In Biotech

Drug Trial Radar · NCT07905924

A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) Mutation

A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RO7836748 as Monotherapy and in Combination With Other Anti-Cancer Therapies in Participants With Advanced Solid Tumors With a RAS G12V Mutation

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 540 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

540

Planned (sponsor's estimate)

Start

Dec 31, 2026

Primary completion

Mar 30, 2032

Study completion Mar 30, 2032

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Oct 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of RO7836748 as monotherapy and in combination with other anti-cancer therapies, including cetuximab, pembrolizumab, or modified (m)FOLFIRINOX in participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12V-positive solid tumors such as non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC), and other solid tumors.

Conditions

  • Solid Tumors

Interventions

  • RO7836748Drug

    Participants will receive RO7836748 as per the schedule described in the protocol.

  • PembrolizumabDrug

    Participants will receive pembrolizumab as per the schedule described in the protocol.

  • mFOLFIRINOXDrug

    Participants will receive mFOLFIRINOX as per the schedule described in the protocol.

  • CetuximabDrug

    Participants will receive cetuximab as per the schedule described in the protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts 1A and 1B: Incidence and Severity of Adverse Events (AEs)Time frame: From first dose up to approximately 5 years
  2. Part 2: Incidence and Severity of AEsTime frame: From first dose up to approximately 5 years
  3. Parts 3A, 3B and 3C: Incidence and Severity of AEsTime frame: From first dose up to approximately 5 years
  4. Parts 1A and 1B: Incidence of Dose-limiting Toxicities (DLTs)Time frame: From Cycle 1 Day 1 (C1D1) until C1D21 (Cycle 1 = 21 days)
  5. Part 3A: Incidence of DLTsTime frame: From C1D1 until C1D21 (Cycle 1 = 21 days)
  6. Parts 3B and 3C: Incidence of DLTsTime frame: From C1D1 until C1D28 (Cycle 1 = 28 days)
  7. Parts 1A and 1B: Recommended Dose for Expansion (RDE) of RO7836748 MonotherapyTime frame: Up to approximately 5 years
  8. Parts 3A, 3B, 3C: RDE of RO7836748 in Combination With Other Anti-Cancer TherapiesTime frame: Up to approximately 5 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.